RXO, Inc.
RXO, Inc. (RXO) Financial Performance & Income Statement Overview
Analyze RXO, Inc. (RXO) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
RXO, Inc. (RXO) Income Statement & Financial Overview
View the income breakdown for RXO, Inc. RXO across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $1.43B | $1.67B | $1.04B | $930.00M |
| Cost of Revenue | $1.23B | $1.44B | $879.00M | $717.00M |
| Gross Profit | $200.00M | $227.00M | $161.00M | $213.00M |
| Gross Profit Ratio | $0.14 | $0.14 | $0.15 | $0.23 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $210.00M | $218.00M | $149.00M | $204.00M |
| Operating Expenses | $230.00M | $251.00M | $181.00M | $204.00M |
| Total Costs & Expenses | $1.46B | $1.69B | $1.06B | $921.00M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $9.00M | $8.00M | $6.00M | $8.00M |
| Depreciation & Amortization | $32.00M | $33.00M | $809000.00 | $17.00M |
| EBITDA | $2.00M | $8.00M | $573000.00 | $26.00M |
| EBITDA Ratio | $0.001 | $0.005 | $0.001 | $0.03 |
| Operating Income | -$30.00M | -$24.00M | -$20.00M | $9.00M |
| Operating Income Ratio | -$0.02 | -$0.01 | -$0.02 | $0.010 |
| Other Income/Expenses (Net) | -$9.00M | -$9.00M | -$222.00M | -$17.00M |
| Income Before Tax | -$39.00M | -$33.00M | -$242.00M | -$8.00M |
| Income Before Tax Ratio | -$0.03 | -$0.02 | -$0.23 | -$0.009 |
| Income Tax Expense | -$8.00M | -$8.00M | $1.00M | -$1.00M |
| Net Income | -$31.00M | -$25.00M | -$243.00M | -$7.00M |
| Net Income Ratio | -$0.02 | -$0.01 | -$0.23 | -$0.008 |
| EPS | -$0.18 | -$0.12 | -$1.81 | -$0.06 |
| Diluted EPS | -$0.18 | -$0.12 | -$1.81 | -$0.06 |
| Weighted Avg Shares Outstanding | $168.02M | $164.41M | $134.09M | $117.58M |
| Weighted Avg Shares Outstanding (Diluted) | $168.02M | $164.41M | $134.09M | $117.58M |
Over the past four quarters, RXO, Inc. demonstrated steady revenue growth, increasing from $930.00M in Q2 2024 to $1.43B in Q1 2025. Operating income reached -$30.00M in Q1 2025, maintaining a consistent -2% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $2.00M, reflecting operational efficiency. Net income dropped to -$31.00M, with EPS at -$0.18. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan